DK0843557T3 - Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein - Google Patents
Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 proteinInfo
- Publication number
- DK0843557T3 DK0843557T3 DK96926748T DK96926748T DK0843557T3 DK 0843557 T3 DK0843557 T3 DK 0843557T3 DK 96926748 T DK96926748 T DK 96926748T DK 96926748 T DK96926748 T DK 96926748T DK 0843557 T3 DK0843557 T3 DK 0843557T3
- Authority
- DK
- Denmark
- Prior art keywords
- lag
- lymphocytes
- methods
- cells
- targeting
- Prior art date
Links
- 210000004698 lymphocyte Anatomy 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 102000017578 LAG3 Human genes 0.000 title 1
- 101150030213 Lag3 gene Proteins 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 238000002955 isolation Methods 0.000 title 1
- 238000002372 labelling Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102100037850 Interferon gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 108090000978 Interleukin-4 Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 210000000447 Th1 cell Anatomy 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000000822 natural killer cell Anatomy 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/811—Test for named disease, body condition or organ function
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US136795P | 1995-07-21 | 1995-07-21 | |
| US268395P | 1995-09-21 | 1995-09-21 | |
| PCT/US1996/011994 WO1997003695A1 (en) | 1995-07-21 | 1996-07-19 | Methods for detecting, identifying, isolating, and selectively labelling and targeting th1 lymphocytes by means of the lag-3 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0843557T3 true DK0843557T3 (da) | 2003-03-10 |
Family
ID=26668940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK96926748T DK0843557T3 (da) | 1995-07-21 | 1996-07-19 | Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6197524B1 (da) |
| EP (1) | EP0843557B1 (da) |
| JP (2) | JP2000508226A (da) |
| AT (1) | ATE227586T1 (da) |
| AU (1) | AU701375B2 (da) |
| CA (1) | CA2227334A1 (da) |
| DE (1) | DE69624824T2 (da) |
| DK (1) | DK0843557T3 (da) |
| ES (1) | ES2186797T3 (da) |
| IL (1) | IL122832A (da) |
| PT (1) | PT843557E (da) |
| WO (1) | WO1997003695A1 (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9810371B (en) * | 1997-11-13 | 1999-08-30 | Schering Corp | Th2 cell depletion; compositions; methods. |
| EP1295895B1 (en) * | 2001-09-19 | 2011-08-10 | Institut Gustave Roussy | Peptides and proteins binding to glu-pro motifs, therapeutical compositions containing the same and applications thereof |
| KR100615389B1 (ko) * | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| AU2004217526B2 (en) * | 2003-02-28 | 2010-02-04 | St. Jude Children's Research Hospital Inc. | T cell regulation |
| US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| EP1987839A1 (en) * | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| JP6660080B2 (ja) * | 2010-07-01 | 2020-03-04 | リジェネレイティブ リサーチ ファウンデーション | 持続放出組成物を用いる未分化細胞培養方法 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| ES2808654T3 (es) | 2013-03-15 | 2021-03-01 | Glaxosmithkline Ip Dev Ltd | Proteínas de unión anti-LAG-3 |
| KR20210141789A (ko) | 2013-09-20 | 2021-11-23 | 브리스톨-마이어스 스큅 컴퍼니 | 종양을 치료하기 위한 항-lag-3 항체 및 항-pd-1 항체의 조합물 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| WO2015123654A1 (en) | 2014-02-17 | 2015-08-20 | The Cleveland Clinic Foundation | Amine passivated nanoparticles for cancer treatment and imaging |
| PH12016501545B1 (en) | 2014-03-14 | 2023-12-06 | Immutep Sas | Antibody molecules to lag-3 and uses thereof |
| MX377844B (es) | 2014-05-28 | 2025-03-11 | Agenus Inc | Anticuerpos anti proteína relacionada con el receptor del factor de necrosis tumoral inducida por glucocorticóides (gitr) y sus métodos de uso. |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
| CN108699145A (zh) | 2015-09-02 | 2018-10-23 | 伊缪泰普有限公司 | 抗lag-3抗体 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods for using them |
| MX2018007406A (es) | 2015-12-16 | 2018-08-15 | Merck Sharp & Dohme | Anticuerpos anti-lag3 y fragmentos de enlace al antigeno. |
| KR20230133934A (ko) | 2016-10-11 | 2023-09-19 | 아게누스 인코포레이티드 | 항-lag-3 항체 및 이의 사용 방법 |
| IL313695A (en) | 2017-02-10 | 2024-08-01 | Regeneron Pharma | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| CN118356488A (zh) | 2017-05-30 | 2024-07-19 | 百时美施贵宝公司 | 包含抗lag-3抗体或抗lag-3抗体和抗pd-1或抗pd-l1抗体的组合物 |
| HUE065242T2 (hu) | 2017-05-30 | 2024-05-28 | Bristol Myers Squibb Co | LAG-3-pozitív tumorok kezelése |
| SG11202111262XA (en) | 2019-05-13 | 2021-11-29 | Regeneron Pharma | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer |
| WO2024192033A1 (en) | 2023-03-13 | 2024-09-19 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2656800B1 (fr) * | 1990-01-08 | 1992-05-15 | Roussy Inst Gustave | Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques. |
| ATE352617T1 (de) * | 1994-05-06 | 2007-02-15 | Roussy Inst Gustave | Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper |
-
1996
- 1996-07-19 JP JP9506911A patent/JP2000508226A/ja active Pending
- 1996-07-19 US US08/983,576 patent/US6197524B1/en not_active Expired - Lifetime
- 1996-07-19 AT AT96926748T patent/ATE227586T1/de active
- 1996-07-19 DE DE69624824T patent/DE69624824T2/de not_active Expired - Lifetime
- 1996-07-19 WO PCT/US1996/011994 patent/WO1997003695A1/en not_active Ceased
- 1996-07-19 PT PT96926748T patent/PT843557E/pt unknown
- 1996-07-19 EP EP96926748A patent/EP0843557B1/en not_active Expired - Lifetime
- 1996-07-19 AU AU66784/96A patent/AU701375B2/en not_active Expired
- 1996-07-19 CA CA002227334A patent/CA2227334A1/en not_active Abandoned
- 1996-07-19 DK DK96926748T patent/DK0843557T3/da active
- 1996-07-19 ES ES96926748T patent/ES2186797T3/es not_active Expired - Lifetime
- 1996-07-19 IL IL122832A patent/IL122832A/en not_active IP Right Cessation
-
2007
- 2007-11-07 JP JP2007289509A patent/JP2008150362A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997003695A1 (en) | 1997-02-06 |
| JP2008150362A (ja) | 2008-07-03 |
| AU6678496A (en) | 1997-02-18 |
| EP0843557A1 (en) | 1998-05-27 |
| CA2227334A1 (en) | 1997-02-06 |
| EP0843557A4 (en) | 1999-04-14 |
| ES2186797T3 (es) | 2003-05-16 |
| US6197524B1 (en) | 2001-03-06 |
| PT843557E (pt) | 2003-03-31 |
| IL122832A0 (en) | 1998-08-16 |
| IL122832A (en) | 2006-08-20 |
| AU701375B2 (en) | 1999-01-28 |
| JP2000508226A (ja) | 2000-07-04 |
| DE69624824T2 (de) | 2003-09-11 |
| DE69624824D1 (de) | 2002-12-19 |
| EP0843557B1 (en) | 2002-11-13 |
| ATE227586T1 (de) | 2002-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0843557T3 (da) | Fremgangsmåder til detektion, identifikation, isolation og selektiv mærkning og målsøgning af Th1-lymfocytter ved hjælp af LAG-3 protein | |
| Thiel et al. | Immunomagnetic cell sorting—pushing the limits | |
| Povoleri et al. | Human retinoic acid–regulated CD161+ regulatory T cells support wound repair in intestinal mucosa | |
| Prussin | Cytokine flow cytometry: understanding cytokine biology at the single-cell level | |
| US7575870B1 (en) | Assay method for peptide specific T-cells | |
| Evans et al. | Detection, isolation, and functional characterization of two human T-cell subclasses bearing unique differentiation antigens. | |
| Sizemore et al. | Phylogeny of lymphocyte heterogeneity: the cellular requirements for in vitro mitogenic responses of channel catfish leukocytes. | |
| Majewska et al. | Lymphocytic, cytokine and transcriptomic profiles in peripheral blood of dogs with atopic dermatitis | |
| Yu et al. | EdU incorporation is an alternative non-radioactive assay to [3H] thymidine uptake for in vitro measurement of mice T-cell proliferations | |
| Jones et al. | Differential regulation of the interleukin-12 receptor during the innate immune response to Leishmania major | |
| Turner et al. | Circulating CD14brightCD16+ ‘intermediate’monocytes exhibit enhanced parasite pattern recognition in human helminth infection | |
| Chiacchio et al. | Impact of antiretroviral and tuberculosis therapies on CD4+ and CD8+ HIV/M. tuberculosis-specific T-cell in co-infected subjects | |
| Moussa et al. | Placental cytokine and chemokine production in HIV-1-infected women: trophoblast cells show a different pattern compared to cells from HIV-negative women | |
| Choi et al. | Tumor necrosis factor-producing T-regulatory cells are associated with severe liver injury in patients with acute hepatitis A | |
| MAINI et al. | A comparison of two techniques for the molecular tracking of specific T‐cell responses; CD4+ human T‐cell clones persist in a stable hierarchy but at a lower frequency than clones in the CD8+ population | |
| Tischer et al. | Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection | |
| Le et al. | Production of soluble HLA‐class‐I molecules by IFN‐γ‐induced colon‐adenocarcinoma cells | |
| Oliveira et al. | Basal activation of type I interferons (alpha2 and beta) and 2′ 5′ OAS genes: insights into differential expression profiles of interferon system components in systemic sclerosis | |
| JPH10505905A (ja) | 免疫細胞の増殖性老化の診断試験 | |
| Taechasan et al. | The alteration of NK cells phenotypes related to the functions and dengue disease outcomes | |
| Jayasinghe et al. | Single cell resolution analysis of multi-tissue derived human iNKT cells reveals novel transcriptional paradigms | |
| Dembek et al. | Nef-specific CD45RA+ CD8+ T cells secreting MIP-1β but not IFN-γ are associated with nonprogressive HIV-1 infection | |
| AU2003302440A8 (en) | Nucleic acid probes and method for detecting a target nucleic acid sequence comprise two or more cis- located nucleic acid regions | |
| Marshall | Novel mechanistic insights into the role of T cells in the pathogenesis of Juvenile Dermatomyositis | |
| ATE237139T1 (de) | Verfahren zur identifizierung personen empfindlich für betahemolytischer streptococci- vermittelter neuropsychiatrischer krankheiten |